These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 33101298)

  • 21. Hypoxia-related signature to risk stratify patients for the benefit of immune checkpoint inhibitors therapy in head and neck squamous cell carcinoma: An experimental study.
    Zhao Y; Yang Z; Fu M; Wu S; Wang M; Li J; Wang Z; Li W
    Medicine (Baltimore); 2024 Aug; 103(31):e39184. PubMed ID: 39093745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FAT1 as a tumor mutation burden specific gene affects the immunotherapy effect in head and neck squamous cell cancer.
    Cao H; Lan T; Kuang S; Wang L; Li J; Li Q; Li Y; Xu Q; Chen Q; Ren S; Lan C; Ouyang N; Liao J; Huang Y; Li J
    Drug Resist Updat; 2024 Sep; 76():101095. PubMed ID: 38986165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD244 represents a new therapeutic target in head and neck squamous cell carcinoma.
    Agresta L; Lehn M; Lampe K; Cantrell R; Hennies C; Szabo S; Wise-Draper T; Conforti L; Hoebe K; Janssen EM
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel immune-related long non-coding RNA signature improves the prognosis prediction in the context of head and neck squamous cell carcinoma.
    Chen L; Cai Z; Lyu K; Cai Z; Lei W
    Bioengineered; 2021 Dec; 12(1):2311-2325. PubMed ID: 34167440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell surface markers for T and B lymphocytes activation and adhesion as putative prognostic biomarkers for head and neck squamous cell carcinoma.
    Andrade MC; Ferreira SB; Gonçalves LC; De-Paula AM; de Faria ES; Teixeira-Carvalho A; Martins-Filho OA
    Hum Immunol; 2013 Dec; 74(12):1563-74. PubMed ID: 23994583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Host derived macrophage migration inhibitory factor expression attenuates anti-tumoral immune cell accumulation and promotes immunosuppression in the tumor microenvironment of head and neck squamous cell carcinoma.
    Ryan N; Lamenza F; Shrestha S; Upadhaya P; Springer A; Jordanides P; Pracha H; Roth P; Kumar R; Wang Y; Vilgelm AE; Satoskar A; Oghumu S
    Biochim Biophys Acta Mol Basis Dis; 2024 Oct; 1870(7):167345. PubMed ID: 38992847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An immune-related seven-lncRNA signature for head and neck squamous cell carcinoma.
    Chen Y; Luo TQ; Xu SS; Chen CY; Sun Y; Lin L; Mao YP
    Cancer Med; 2021 Apr; 10(7):2268-2285. PubMed ID: 33660378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and analysis of genes associated with head and neck squamous cell carcinoma by integrated bioinformatics methods.
    Jin Y; Yang Y
    Mol Genet Genomic Med; 2019 Aug; 7(8):e857. PubMed ID: 31304688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highlighting immune features of the tumor ecosystem and prognostic value of Tfh and Th17 cell infiltration in head and neck squamous cell carcinoma by single-cell RNA-seq.
    Tian Y; Liu C; Yang W; Li X; Zhang M; Xiong Y; Ren X; Ma Z; Jin X; Wu Y; Dong X; Hu N; Xie Z; Qin Y; Wu S
    Cancer Immunol Immunother; 2024 Aug; 73(10):187. PubMed ID: 39093451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RUVBL1 is an amplified epigenetic factor promoting proliferation and inhibiting differentiation program in head and neck squamous cancers.
    Lin D; Lin B; Bhanot H; Riou R; Abt NB; Rajagopal J; Saladi SV
    Oral Oncol; 2020 Dec; 111():104930. PubMed ID: 32745900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SLC13A4 Might Serve as a Prognostic Biomarker and be Correlated with Immune Infiltration into Head and Neck Squamous Cell Carcinoma.
    Yang ML; Zhang JH; Li S; Zhu R; Wang L
    Pathol Oncol Res; 2021; 27():1609967. PubMed ID: 34840533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic landscape of head and neck squamous cell carcinoma informs a novel kynurenine/Siglec-15 axis in immune escape.
    Zhang XY; Shi JB; Jin SF; Wang RJ; Li MY; Zhang ZY; Yang X; Ma HL
    Cancer Commun (Lond); 2024 Jun; 44(6):670-694. PubMed ID: 38734931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative analysis of the tumor microbiome, molecular profiles, and immune cell abundances by HPV status in mucosal head and neck cancers and their impact on survival.
    Upadhyay R; Dhakal A; Wheeler C; Hoyd R; Jagjit Singh M; Karivedu V; Bhateja P; Bonomi M; Valentin S; Gamez ME; Konieczkowski DJ; Baliga S; Grecula JC; Blakaj DM; Gogineni E; Mitchell DL; Denko NC; Spakowicz D; Jhawar SR
    Cancer Biol Ther; 2024 Dec; 25(1):2350249. PubMed ID: 38722731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells.
    Payne KK; Mine JA; Biswas S; Chaurio RA; Perales-Puchalt A; Anadon CM; Costich TL; Harro CM; Walrath J; Ming Q; Tcyganov E; Buras AL; Rigolizzo KE; Mandal G; Lajoie J; Ophir M; Tchou J; Marchion D; Luca VC; Bobrowicz P; McLaughlin B; Eskiocak U; Schmidt M; Cubillos-Ruiz JR; Rodriguez PC; Gabrilovich DI; Conejo-Garcia JR
    Science; 2020 Aug; 369(6506):942-949. PubMed ID: 32820120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioinformatic analysis identifies HPV-related tumor microenvironment remodeling prognostic biomarkers in head and neck squamous cell carcinoma.
    Zhou Q; Yuan O; Cui H; Hu T; Xiao GG; Wei J; Zhang H; Wu C
    Front Cell Infect Microbiol; 2022; 12():1007950. PubMed ID: 36425786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and genomic characterization of neutral tumor evolution in Head and Neck Squamous Cell Carcinoma.
    Li R; Dong J; Zhang H; Zhao Q; Li X; Liu X; Ye Y; Deng S; Lin D; Zheng J; Zuo Z
    Genomics; 2020 Sep; 112(5):3448-3454. PubMed ID: 32569729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis.
    Chen X; Yan B; Lou H; Shen Z; Tong F; Zhai A; Wei L; Zhang F
    Mol Immunol; 2018 Apr; 96():28-36. PubMed ID: 29477933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimation of immune cell content in tumor using single-cell RNA-seq reference data.
    Yu X; Chen YA; Conejo-Garcia JR; Chung CH; Wang X
    BMC Cancer; 2019 Jul; 19(1):715. PubMed ID: 31324168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.